Harvey I. Pass, MD | Authors

May 13, 2022

Expert perspectives on the IMpower010 and KEYNOTE-091 trials, which assessed adjuvant immunotherapy in non–small cell lung cancer.

May 13, 2022

Shared insight on the CheckMate-816 trial and how immunotherapy may have a role in the neoadjuvant setting of non–small cell lung cancer.

May 06, 2022

A broad discussion on the role of immunotherapy in newly diagnosed NSCLC in both the neoadjuvant and adjuvant settings.

May 06, 2022

Shared insight on a patient profile of newly diagnosed non–small cell lung cancer with high PD-L1 expression and no driver mutation.

April 29, 2022

Expert panelists look at all factors that inform treatment selection when managing a patient diagnosed with non–small cell lung cancer.

April 29, 2022

Comprehensive discussion on how biomarker testing and multidisciplinary care can improve the management of non–small cell lung cancer.

June 23, 2011

In this exclusive video, Dr. Harvey Pass discusses surgery in mesothelioma of the pleura and other areas of disagreement.

October 01, 1999

Chemotherapy agents known to enhance the effects of radiation in preclinical studies have been used concurrently with radiotherapy in numerous clinical trials with the prospect of further enhancing radiation-induced